NewsBenzinga엔베릭 바이오사이언스, 주요 정신질환 치료제 후보물질의 뇌 활동 데이터 긍정적 결과 발표 엔베릭 바이오사이언스, 주요 정신질환 치료제 후보물질의 뇌 활동 데이터 긍정적 결과 발표 Benzinga 2026.11.04 13:02 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Overweight on Ashland, Raises Price Target to $82 JP Morgan Maintains Neutral on ArcBest, Raises Price Target to $164 JP Morgan Maintains Overweight on Dave, Lowers Price Target to $435 Chip Stocks Just Had Their Worst Day Since 2020: 28 of 30 Biggest Names Are in a Bear Market $1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today JP Morgan Maintains Underweight on Avis Budget Gr, Lowers Price Target to $85
